Posttraumatic stress disorder (PTSD) has been described as the only neuropsychiatric disorder with a known cause, yet effective behavioral and pharmacotherapies remain elusive for many afflicted individuals. PTSD is characterized by heightened noradrenergic signaling, as well as a resistance to extinction learning. Research aimed at promoting more effective treatment of PTSD has focused on memory erasure (disrupting reconsolidation) and/or enhancing extinction retention through pharmacological manipulations. Propranolol, a b-adrenoceptor antagonist, has received considerable attention for its therapeutic potential in PTSD, although its impact on patients is not always effective. In this review, we briefly examine the consequences of b-noradrenergic manipulations on both reconsolidation and extinction learning in rodents and in humans. We suggest that propranolol is effective as a fear-reducing agent when paired with behavioral therapy soon after trauma when psychological stress is high, possibly preventing or dampening the later development of PTSD. In individuals who have already suffered from PTSD for a significant period of time, propranolol may be less effective at disrupting reconsolidation of strong fear memories. Also, when PTSD has already developed, chronic treatment with propranolol may be more effective than acute intervention, given that individuals with PTSD tend to experience long-term, elevated noradrenergic hyperarousal.
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Introduction
Posttraumatic stress disorder (PTSD) affects approximately 8% of the United States general population in their lifetime (Kessler, Sonnega, Bromet, Hughes, & Nelson, 1995; Kessler et al., 2005) , and is characterized by heightened arousal and a resistance to extinction learning (Liberzon & Sripada, 2008; Pitman et al., 2012; Rauch, Shin, & Phelps, 2006; Shin & Handwerger, 2009; VanElzakker, Dahlgren, Davis, Dubois, & Shin, 2014) . While the pathophysiology of PTSD is poorly understood, dysregulated signaling of the stress-related neurotransmitter norepinephrine (NE) has been identified as a key biomarker underlying PTSD symptomatology (Geracioti et al., 2001; Kosten, Mason, Giller, Ostroff, & Harkness, 1987; Southwick et al., 1997; Southwick et al., 1999; Yehuda, Southwick, Giller, Ma, & Mason, 1992) . However, the only FDA approved treatments for PTSD are the selective serotonin reuptake inhibitors, sertraline (Zoloft) and paroxetine (Paxil), which have limited efficacy (Tawa & Murphy, 2013) . Nonetheless, pharmacotherapies that either dampen NE transmission, such as the a1-adrenoceptor antagonist prazosin, the a2 agonist clonidine, and the non-selective b antagonist propranolol, or enhance NE transmission such as the a2 antagonist yohimbine, have shown some success in diminishing the exaggerated fear responding associated with PTSD (Belkin & Schwartz, 2015; Morris & Bouton, 2007; Powers, Smits, Otto, Sanders, & Emmelkamp, 2009; Raskind et al., 2003; Strawn & Geracioti, 2008; Tawa & Murphy, 2013; Taylor, Freeman, & Cates, 2008; Wangelin, Powers, Smits, & Tuerk, 2013) . Yohimbine, as well as the non-selective b agonist isoproterenol, can enhance extinction learning (Cain, Blouin, & Barad, 2004; Do-Monte et al., 2010; Morris & Bouton, 2007; Powers et al., 2009) , as well as memory consolidation or reconsolidation (Dę biec, Bush, & LeDoux, 2011; Gazarini, Stern, Carobrez, & Bertoglio, 2013) . For these reasons, there has been a resurgence of interest in using noradrenergic drugs as adjuncts to cognitivebehavioral therapies for PTSD.
In this regard, animal studies of inhibitory avoidance, and Pavlovian fear conditioning studies in both animals and humans have provided insight into the neurobiological underpinnings of aversive learning and memory that contribute to the development and expression of PTSD (Bowers & Ressler, 2015; Fanselow & Poulos, 2005; LeDoux, 2000; Maren, 2001; Maren, Phan, & 
